$USNU
Elite Health Systems Inc.

2019 Q4 Form 10-K Financial Statement

#000114036120008735 Filed on April 13, 2020

View on sec.gov

Income Statement

Concept 2019 Q4 2019 2018 Q4
Revenue $746.0K $3.070M $635.0K
YoY Change 17.48% -10.34%
Cost Of Revenue $101.0K $350.0K $79.00K
YoY Change 27.85% -73.9%
Gross Profit $645.0K $2.720M $556.0K
YoY Change 16.01% 30.58%
Gross Profit Margin 86.46% 88.6% 87.56%
Selling, General & Admin $270.0K $1.230M $355.0K
YoY Change -23.94% -4.58%
% of Gross Profit 41.86% 45.22% 63.85%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
% of Gross Profit 0.0% 0.0% 0.0%
Operating Expenses $270.0K $1.580M $1.018M
YoY Change -73.48% -52.02%
Operating Profit $375.0K $1.490M -$462.0K
YoY Change -181.17% 1037.4%
Interest Expense -$569.0K $91.00K -$368.0K
YoY Change 54.62% -19.47%
% of Operating Profit -151.73% 6.11%
Other Income/Expense, Net
YoY Change
Pretax Income -$194.0K $151.0K -$830.0K
YoY Change -76.63% -124.63%
Income Tax -$94.00K $9.000K -$390.0K
% Of Pretax Income 5.96%
Net Earnings -$100.0K $142.0K -$440.0K
YoY Change -77.27% -133.73%
Net Earnings / Revenue -13.4% 4.63% -69.29%
Basic Earnings Per Share
Diluted Earnings Per Share -$12.83K $18.22K -$56.47K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q4 2019 2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.335M $1.335M $1.519M
YoY Change -12.11% -12.11% -43.32%
Cash & Equivalents $1.335M $1.335M $1.519M
Short-Term Investments
Other Short-Term Assets $102.0K $102.0K $154.0K
YoY Change -33.77% -33.77% 120.0%
Inventory
Prepaid Expenses
Receivables $356.0K $356.0K $318.0K
Other Receivables $888.0K $888.0K $929.0K
Total Short-Term Assets $2.681M $2.681M $4.061M
YoY Change -33.98% -33.98% 1.78%
LONG-TERM ASSETS
Property, Plant & Equipment $128.0K $128.0K $0.00
YoY Change -100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $179.0K $179.0K $168.0K
YoY Change 6.55% 6.55% 5.0%
Other Assets $2.188M $1.439M $2.144M
YoY Change 2.05%
Total Long-Term Assets $2.316M $2.316M $2.144M
YoY Change 8.02% 8.02% -45.45%
TOTAL ASSETS
Total Short-Term Assets $2.681M $2.681M $4.061M
Total Long-Term Assets $2.316M $2.316M $2.144M
Total Assets $4.997M $4.997M $6.205M
YoY Change -19.47% -19.47% -21.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $255.0K $255.0K $227.0K
YoY Change 12.33% 12.33% 8.1%
Accrued Expenses $36.00K $36.00K $0.00
YoY Change
Deferred Revenue $226.0K $255.0K
YoY Change -11.37%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $901.0K $901.0K $1.399M
YoY Change -35.6% -35.6% 44.23%
Total Short-Term Liabilities $1.638M $1.638M $1.881M
YoY Change -12.92% -12.92% 16.83%
LONG-TERM LIABILITIES
Long-Term Debt $89.00K $89.00K $988.0K
YoY Change -90.99% -90.99% -40.84%
Other Long-Term Liabilities $117.0K $117.0K $11.00K
YoY Change 963.64% 963.64% -97.92%
Total Long-Term Liabilities $206.0K $206.0K $999.0K
YoY Change -79.38% -79.38% -54.59%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.638M $1.638M $1.881M
Total Long-Term Liabilities $206.0K $206.0K $999.0K
Total Liabilities $1.844M $1.844M $3.194M
YoY Change -42.27% -42.27% -28.71%
SHAREHOLDERS EQUITY
Retained Earnings -$25.00K -$167.0K
YoY Change -85.03%
Common Stock $3.178M $3.178M
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.153M $3.153M $3.011M
YoY Change
Total Liabilities & Shareholders Equity $4.997M $4.997M $6.205M
YoY Change -19.47% -19.47% -21.65%

Cashflow Statement

Concept 2019 Q4 2019 2018 Q4
OPERATING ACTIVITIES
Net Income -$100.0K $142.0K -$440.0K
YoY Change -77.27% -133.73%
Depreciation, Depletion And Amortization $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Operating Activities $466.0K $1.547M $478.0K
YoY Change -2.51% -32.39% -381.18%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$160.0K -$334.0K -$210.0K
YoY Change -23.81% -81.43% -53.33%
Cash From Investing Activities -$160.0K -$334.0K -$210.0K
YoY Change -23.81% -85.9% -54.35%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -363.0K -1.397M -363.0K
YoY Change 0.0% 28.87% 39.62%
NET CHANGE
Cash From Operating Activities 466.0K 1.547M 478.0K
Cash From Investing Activities -160.0K -334.0K -210.0K
Cash From Financing Activities -363.0K -1.397M -363.0K
Net Change In Cash -57.00K -184.0K -95.00K
YoY Change -40.0% -84.21% -89.33%
FREE CASH FLOW
Cash From Operating Activities $466.0K $1.547M $478.0K
Capital Expenditures $0.00 $0.00 $0.00
Free Cash Flow $466.0K $1.547M $478.0K
YoY Change -2.51% -45.87% -381.18%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019 dei Amendment Flag
AmendmentFlag
false
CY2019 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019 dei Document Period End Date
DocumentPeriodEndDate
2019-12-31
CY2019 dei Entity Address State Or Province
EntityAddressStateOrProvince
MD
CY2019 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2019 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2019 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2019 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2019Q2 dei Entity Public Float
EntityPublicFloat
811000
CY2019 dei Entity Registrant Name
EntityRegistrantName
U.S. NeuroSurgical Holdings, Inc.
CY2019 dei Entity Central Index Key
EntityCentralIndexKey
0001089815
CY2020Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7792185
CY2019 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2019 dei Document Type
DocumentType
10-K
CY2019 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019 dei Entity Shell Company
EntityShellCompany
false
CY2019 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2019 dei Entity Small Business
EntitySmallBusiness
true
CY2018Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
227000
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
255000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
356000
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
318000
CY2019Q4 us-gaap Accounts Receivable Related Parties Noncurrent
AccountsReceivableRelatedPartiesNoncurrent
1422000
CY2018Q4 us-gaap Accounts Receivable Related Parties Noncurrent
AccountsReceivableRelatedPartiesNoncurrent
0
CY2019Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
220000
CY2018Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
0
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3100000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3100000
CY2019 us-gaap Advertising Expense
AdvertisingExpense
0
CY2018 us-gaap Advertising Expense
AdvertisingExpense
0
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0
CY2019Q4 us-gaap Asset Retirement Obligation
AssetRetirementObligation
0
CY2018Q4 us-gaap Asset Retirement Obligation
AssetRetirementObligation
0
CY2018 us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
20000
CY2019 us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
0
CY2018Q4 us-gaap Assets
Assets
6205000
CY2019Q4 us-gaap Assets
Assets
4997000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
4061000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
2681000
CY2018Q3 us-gaap Assets Of Disposal Group Including Discontinued Operation
AssetsOfDisposalGroupIncludingDiscontinuedOperation
4247000
CY2018 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
0
CY2019 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
176000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2684000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1519000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1335000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1519000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1335000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1165000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-184000
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7792185
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7792185
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7792185
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7792185
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
78000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
78000
CY2019 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"><tr style="vertical-align: top;"><td style="vertical-align: top; width: 27pt;"><div><font style="font-weight: bold;">[16]</font></div></td><td style="align: left; vertical-align: top; width: auto;"><div><font style="font-weight: bold;">Credit risk:</font></div></td></tr></table><div><br /></div><div style="text-align: justify; margin-left: 27pt;">At times, the Company may have cash and cash equivalents at a financial institution in excess of insured limits. The Company places its cash and cash equivalents with high credit quality financial institutions whose credit ratings are monitored by management to minimize credit risk. Accounts receivable consist of amounts due from the medical centers.&#160; Historically, credit losses on accounts receivable have not been significant. At December 31, 2019 and 2018, substantially all of the Company&#8217;s accounts receivable were due from one customer, NYU.</div></div>
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
226000
CY2018Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
255000
CY2015Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
20000
CY2017Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
26000
CY2018 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
169000
CY2019 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
340000
CY2018 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
137000
CY2019 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
69000
CY2019 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
271000
CY2018 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
32000
CY2018Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
0
CY2019Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
17000
CY2019Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
0
CY2018Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
314000
CY2019 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-288000
CY2018 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-201000
CY2018 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-361000
CY2019 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-331000
CY2018Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
314000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
373000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
587000
CY2019Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
17000
CY2019 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-43000
CY2018 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-160000
CY2018Q4 us-gaap Deferred Tax Liabilities Tax Deferred Income
DeferredTaxLiabilitiesTaxDeferredIncome
577000
CY2019Q4 us-gaap Deferred Tax Liabilities Tax Deferred Income
DeferredTaxLiabilitiesTaxDeferredIncome
526000
CY2019 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
14000
CY2018 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
14000
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
0
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
983000
CY2018Q3 us-gaap Disposal Group Including Discontinued Operation Deferred Revenue
DisposalGroupIncludingDiscontinuedOperationDeferredRevenue
600000
CY2018Q3 us-gaap Disposal Group Including Discontinued Operation Capital Leased Assets
DisposalGroupIncludingDiscontinuedOperationCapitalLeasedAssets
898000
CY2018Q3 us-gaap Disposal Group Including Discontinued Operation Property Plant And Equipment
DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
3349000
CY2019Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
0
CY2018Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
1141000
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.02
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.05
CY2018 us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
60000
CY2019 us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
76000
CY2019Q4 us-gaap Equity Method Investments
EquityMethodInvestments
179000
CY2018Q4 us-gaap Equity Method Investments
EquityMethodInvestments
168000
CY2018 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
100000
CY2019 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
0
CY2019Q4 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
23000
CY2018Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1399000
CY2019Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
901000
CY2019Q4 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
0
CY2019Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.04555
CY2019Q4 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
0
CY2019Q4 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
90000
CY2019Q4 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
1013000
CY2018Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
988000
CY2019Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
89000
CY2019Q4 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
923000
CY2019Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
990000
CY2019 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
0
CY2018 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-663000
CY2019 us-gaap Health Care Organization Expenses Net
HealthCareOrganizationExpensesNet
350000
CY2018 us-gaap Health Care Organization Expenses Net
HealthCareOrganizationExpensesNet
1341000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
151000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-613000
CY2019 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1386000
CY2018 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-743000
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-192000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9000
CY2019 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
32000
CY2018 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-128000
CY2019 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
-26000
CY2018 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
0
CY2018 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-55000
CY2019 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
10000
CY2018Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
101000
CY2019Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
0
CY2019 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
-7000
CY2018 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
-9000
CY2018 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
339000
CY2019 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
158000
CY2019 us-gaap Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable
321000
CY2018 us-gaap Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable
-165000
CY2019 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-178000
CY2018 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
87000
CY2018 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
485000
CY2019 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-29000
CY2019 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
200000
CY2018 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
0
CY2018 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-449000
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
38000
CY2018 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-81000
CY2019 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
43000
CY2019 us-gaap Interest Expense
InterestExpense
91000
CY2018 us-gaap Interest Expense
InterestExpense
113000
CY2018 us-gaap Interest Paid Net
InterestPaidNet
122000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
94000
CY2018 us-gaap Investment Income Interest
InvestmentIncomeInterest
70000
CY2018Q4 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
38000
CY2019 us-gaap Investment Income Interest
InvestmentIncomeInterest
6000
CY2018Q3 us-gaap Liabilities Of Disposal Group Including Discontinued Operation
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
1137000
CY2019Q4 us-gaap Liabilities
Liabilities
1844000
CY2018Q4 us-gaap Liabilities
Liabilities
3194000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4997000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6205000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2369000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1397000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1084000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-421000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
142000
CY2018Q4 us-gaap Notes Receivable Related Parties Noncurrent
NotesReceivableRelatedPartiesNoncurrent
517000
CY2019Q4 us-gaap Notes Receivable Related Parties Noncurrent
NotesReceivableRelatedPartiesNoncurrent
0
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
43000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
24000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
158000
CY2019Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
16000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
46000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
45000
CY2019 us-gaap Lease Cost
LeaseCost
0
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1638000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1881000
CY2019 us-gaap Malpractice Insurance Annual Coverage Limit
MalpracticeInsuranceAnnualCoverageLimit
3000000
CY2019 us-gaap Nature Of Operations
NatureOfOperations
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-weight: bold;">Note A &#8211; Organization and Business</div><div><br /></div><div style="text-align: justify;">U.S. NeuroSurgical Holdings, Inc. owns and operates, through its wholly-owned subsidiaries, stereotactic radiosurgery centers, utilizing gamma knife technology, and holds other interests in radiological treatment facilities.&#160; As used herein, unless the context indicates otherwise, the term &#8220;Company&#8221;, &#8220;Registrant&#8221; and &#8220;Holdings&#8221; means U.S. NeuroSurgical Holdings, Inc. and its wholly-owned subsidiary, U.S. NeuroSurgical, Inc. (&#8220;USN&#8221;), and the wholly-owned subsidiaries of USN, U.S. NeuroSurgical Physics, Inc. and USN Corona, Inc.</div><div><br /></div><div style="text-align: justify;">U.S. NeuroSurgical, Inc. a Delaware corporation, was organized in July 1993 for the purpose of owning and operating stereotactic radiosurgery centers, utilizing the gamma knife technology.&#160; USN holds an interest in one gamma knife center on the premises of New York University Medical Center (&#8220;NYU&#8221;) in New York, New York.&#160; Management continues to explore opportunities to organize and participate in additional gamma knife centers.&#160; USN&#8217;s business strategy is to provide a mechanism whereby hospitals, physicians, and patients can have access to gamma knife treatment capability, a high capital cost item.&#160; USN provides the gamma knife to medical facilities on a &#8220;cost per treatment&#8221; basis.&#160; USN holds an interest in the gamma knife unit and is reimbursed by the facility where it is housed, based on utilization.</div><div><br /></div><div style="text-align: justify;">During the fourth quarter of 2007, USN formed a wholly-owned subsidiary, USN Corona, Inc. (&#8220;USNC&#8221;), to carry investments in Corona Gamma Knife, LLC and NeuroPartners, LLC. Those investments were formed to develop and manage a gamma knife center at San Antonio Regional Hospital in Upland, California. (See Note C[1])</div><div><br /></div><div style="text-align: justify;">During 2010, through the formation of a joint venture, in which it has a noncontrolling interest, the Company expanded its market strategy to include opportunities to develop cancer centers featuring radiation therapy. These centers utilize linear accelerators with IMRT (Intensity Modulated Radiation Therapy) and IGRT (Image Guided Radiation Therapy) capabilities. In 2010, the Company formed Florida Oncology Partners, LLC (&#8220;FOP&#8221;) in partnership with local physicians and other investors. USNC owns a 24% interest in the venture. FOP&#8217;s first center was located in Miami, Florida and opened in the second quarter of 2011. The Company entered into an arrangement to sell the center to 21<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup> Century Oncology in December 2015. The sale had not occurred as of December 31, 2019. (See Note C[2])</div><div><br /></div><div style="text-align: justify;">During 2011, the Company participated in the formation of Boca Oncology Partners RE, LLC (&#8220;BOPRE&#8221;), for the purpose of acquiring an interest in Boca West, IMP, LLC, (&#8220;Boca West, IMP&#8221;) which owns a medical office building. (See Note C[3]).</div><div><br /></div><div style="text-align: justify;">In 2015, Medical Oncology Partners LLC (&#8220;MOP&#8221;), was formed in partnership with local physicians and other investors. MOP was established to acquire a 100% equity interest in United Oncology Medical Associates of Florida, LLC (&#8220;UOMA&#8221;). USNC was not a member of MOP at the time of its formation, as it was not able to participate in MOP&#8217;s formation due to the fact that USNC was not a physician. An application was filed for a waiver and on December 22, 2016, USNC was cleared to become a part owner of MOP. USNC currently owns 35.83% of MOP. (See Note C[4])</div><div><br /></div><div style="text-align: justify;">On September&#160;3, 2015, pursuant to the Agreement and Plan of Reorganization (the &#8220;Merger Agreement&#8221;), dated as of September&#160;3, 2015, by and among USN, Holdings and U.S. NeuroSurgical Merger Sub,&#160;Inc. (&#8220;Merger Sub&#8221;), the Company adopted a new holding company organizational structure whereby USN is now a wholly owned subsidiary of Holdings. This structure did not result in any changes to the assets or operations of the Company, but management believes that it will create a more flexible framework for possible future transactions and organizational and operational adjustments.</div><div style="text-align: justify;">&#160;</div><div style="text-align: justify;">The holding company organizational structure was effected by a merger (the &#8220;Merger&#8221;) conducted pursuant to Section&#160;251(g)&#160;of the Delaware General Corporation Law (the &#8220;DGCL&#8221;), which provides for the formation of a holding company structure without a vote of the stockholders of the constituent corporations.&#160; Because the holding company organizational structure occurred at the parent company level, the remainder of the Company&#8217;s subsidiaries, operations and customers were not affected by this transaction.</div><div style="text-align: justify;"><br /></div><div style="text-align: justify;">In order to effect the Merger, USN formed Holdings as its wholly owned subsidiary and Holdings formed Merger Sub as its wholly owned subsidiary.&#160; Under the terms of the Merger Agreement, Merger Sub merged with and into USN, with USN surviving the merger and becoming a direct, wholly owned subsidiary of Holdings.&#160;&#160; Immediately prior to the Merger, Holdings had no assets, liabilities or operations.</div><div><br /></div><div style="text-align: justify;">Pursuant to the Merger Agreement, all of the outstanding capital stock of USN was converted, on a share for share basis, into capital stock of Holdings.&#160; As a result, each former stockholder of USN became the owner of an identical number of shares of capital stock of Holdings, evidencing the same proportional interests in Holdings and having the same designations, rights, powers and preferences, qualifications, limitations and restrictions, as those that the stockholder held in USN.</div><div style="text-align: justify;">&#160;</div><div style="text-align: justify;">Following the Merger, Holdings&#8217; common stock continued to trade on the over-the-counter market and continued to be quoted on the OTC Markets under the same symbol, &#8220;USNU.&#8221;&#160; The conversion of shares of capital stock under the Merger Agreement occurred without an exchange of physical certificates.&#160; Accordingly, physical certificates formerly representing shares of outstanding capital stock of USN are deemed to represent the same number of shares of capital stock of Holdings.</div><div style="text-align: justify;">&#160;</div><div style="text-align: justify;">Pursuant to Section&#160;251(g)&#160;of the DGCL, the provisions of the certificate of incorporation and bylaws of Holdings are substantially identical to those of USN prior to the date on which the Merger Agreement took effect.&#160; The authorized capital stock of Holdings, the designations, rights, powers and preferences of such capital stock, and the qualifications, limitations and restrictions thereof are also substantially identical to those of the capital stock of USN immediately prior to the date of the Merger.&#160; Further, the directors and executive officers of Holdings are the same individuals who were directors and executive officers, respectively, of USN immediately prior to the date of the Merger.</div><div><br /></div><div style="text-align: justify;">Late in 2016, FOP took initial steps toward the development of a new radiation therapy center in Homestead, Florida.&#160; However, late in the third quarter of 2017, it was determined that the business opportunity at this new location should be pursued by a different investor group, and FOP arranged to sell the opportunity to this group.&#160; CB Oncology Partners, LLC (&#8220;CBOP&#8221;) was organized on September 1, 2017 to acquire the assets and rights in this new center from FOP. USNC owns a 24% interest in CBOP.</div><div><br /></div><div style="text-align: justify;">In June 2017, FOP entered into an agreement with a third-party owner of a radiation therapy center located in Miami, Florida, whereby FOP took over the operation of the center effective September 22, 2017, for a ten-year initial term, and up to three additional terms of five years each. FOP abandoned its operations at this radiation center on June 28, 2019 due to continued losses at the site and lack of success in good faith efforts to renegotiate the agreement after several months of discussion.&#160; FOP could be considered in default of the agreement and the third-party owner could pursue action against FOP.&#160; Due to abandoning the operations of the Miami center as well as continued working capital deficits, FOP&#8217;s ability to continue as a going concern will require FOP to restructure debt, raise new capital, and successfully settle the agreement at the center in Miami, Florida. Since these plans are preliminary and have not been approved at this date, there is substantial doubt about FOP&#8217;s ability to continue as a going concern within the next twelve months from the date these financial statements are available to be issued.</div><div><br /></div><div style="text-align: justify;">The Company, through the formation of noncontrolling interests in unconsolidated joint ventures, is currently exploring other opportunities for the establishment of cancer centers using IMRT and/or IGRT in Florida and other parts of the U.S.</div><div style="text-align: justify;"><br /></div><div>The recent outbreak of the novel coronavirus COVID-19 has spread across the globe and has been declared a public health emergency by the World Health Organization and a National Emergency by the President of the United States.&#160; Most states and municipalities in the U.S., including New York, California and Florida, have announced aggressive actions to reduce the spread of the disease, including limiting non-essential gatherings of people, ceasing all non-essential travel, ordering certain businesses and government agencies to cease non-essential operations at physical locations and issuing &#8220;shelter-in-place&#8221; orders, which direct individuals to shelter at their places of residence (subject to limited exceptions).&#160; Across the healthcare industry, resources are being prioritized for the treatment and management of the outbreak.&#160; Consequently, there are delays in delivering Gamma Knife and other radiation therapy treatments.&#160; In addition, the COVID-19 pandemic poses the risk that the Company and its employees, contractors, customers, government and third party payors and others may be prevented from conducting business activities for an indefinite period of time, including due to spread of the disease within these groups or due to shutdowns that have been and may continue to be requested or mandated by governmental authorities.</div><div><br /></div><div style="text-align: justify;">While the healthcare treatments that are provided by the Company are generally critical to the well-being of the patients it serves, a broad, sustained outbreak of COVID-19 could negatively impact results for the following reasons: (i) operations at medical facilities, including those operated by the Company, could be subject to reduced operation or prolonged closure; (ii) medical facilities may defer Gamma Knife and other cancer therapy treatments for non-urgent patient cases in order to allocate resources to the care of patients with COVID-19; (iii) patients may defer or cancel treatments due to real or perceived concerns about the potential spread of COVID-19 in a medical facility setting; (iv) the outbreak could materially impact operations for a sustained period of time due to the current travel bans and restrictions, quarantines, shelter-in-place orders and shutdowns; and/or (v) members of the Company&#8217;s workforce may become ill or have family members who are ill and are absent as a result, or they may elect not to come to work due to the illness affecting others in our office or facilities.</div><div><br /></div><div style="text-align: justify;">The occurrence of any of the foregoing events could have a material adverse effect on our business, financial condition and results of operations. The COVID-19 outbreak and mitigation measures have had and may continue to have an adverse impact on global economic conditions which could have an adverse effect on our business and financial condition.&#160; The extent to which the COVID-19 outbreak impacts our results will depend on future developments that are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity of the virus and the actions to contain its impact.</div></div>
CY2019Q4 us-gaap Net Investment In Lease Current
NetInvestmentInLeaseCurrent
888000
CY2018Q4 us-gaap Net Investment In Lease Current
NetInvestmentInLeaseCurrent
828000
CY2018Q4 us-gaap Net Investment In Lease Noncurrent
NetInvestmentInLeaseNoncurrent
1421000
CY2019Q4 us-gaap Net Investment In Lease Noncurrent
NetInvestmentInLeaseNoncurrent
532000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1547000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2288000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-334000
CY2019Q4 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
38000
CY2018 us-gaap Deconsolidation Gain Or Loss Amount
DeconsolidationGainOrLossAmount
-663000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-167000
CY2018Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
128000
CY2019 us-gaap Operating Lease Expense
OperatingLeaseExpense
43000
CY2018 us-gaap Operating Lease Expense
OperatingLeaseExpense
42000
CY2018 us-gaap Operating Expenses
OperatingExpenses
3293000
CY2019 us-gaap Operating Expenses
OperatingExpenses
1580000
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.05850
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
1490000
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
161000
CY2018 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2019 us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
1397000
CY2018 us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
1084000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
128000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
131000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
36000
CY2018Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0
CY2018Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
106000
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
142000
CY2018Q4 us-gaap Other Assets Current
OtherAssetsCurrent
154000
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
102000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2144000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2188000
CY2018 us-gaap Payments For Proceeds From Loans Receivable
PaymentsForProceedsFromLoansReceivable
436000
CY2019 us-gaap Payments For Proceeds From Loans Receivable
PaymentsForProceedsFromLoansReceivable
-434000
CY2019 us-gaap Payments For Advance To Affiliate
PaymentsForAdvanceToAffiliate
1572000
CY2018 us-gaap Payments For Advance To Affiliate
PaymentsForAdvanceToAffiliate
1557000
CY2019 us-gaap Payments To Acquire Businesses And Interest In Affiliates
PaymentsToAcquireBusinessesAndInterestInAffiliates
25000
CY2018 us-gaap Payments To Acquire Businesses And Interest In Affiliates
PaymentsToAcquireBusinessesAndInterestInAffiliates
4000
CY2019 us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
0
CY2018 us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
570000
CY2019 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"><tr style="vertical-align: top;"><td style="vertical-align: top; width: 27pt;"><div><font style="font-weight: bold;">[17]</font></div></td><td style="align: left; vertical-align: top; width: auto;"><div><font style="font-weight: bold;">Reclassifications:</font></div></td></tr></table><div><br /></div><div style="text-align: justify; margin-left: 27pt;">Certain amounts reported in the prior year consolidated financial statements have been reclassified to conform to the current year&#8217;s presentation.</div></div>
CY2018 us-gaap Proceeds From Collection Of Lease Receivables
ProceedsFromCollectionOfLeaseReceivables
198000
CY2019 us-gaap Proceeds From Collection Of Lease Receivables
ProceedsFromCollectionOfLeaseReceivables
829000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-25000
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3424000
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3070000
CY2018 us-gaap Sales Type Lease Interest Income
SalesTypeLeaseInterestIncome
42000
CY2019 us-gaap Sales Type Lease Interest Income
SalesTypeLeaseInterestIncome
132000
CY2018Q3 us-gaap Sales Type Lease Lease Receivable
SalesTypeLeaseLeaseReceivable
2447000
CY2019 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1230000
CY2018 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1289000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
3153000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
3011000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
3432000
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"><tr style="vertical-align: top;"><td style="vertical-align: top; width: 27pt;"><div><font style="font-weight: bold;">[14]</font></div></td><td style="align: left; vertical-align: top; width: auto;"><div><font style="font-weight: bold;">Estimates and assumptions:</font></div></td></tr></table><div><br /></div><div style="text-align: justify; margin-left: 27pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.&#160; Actual results could differ from those estimates.</div></div>
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7792185
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7792185
CY2019 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
0
CY2018 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
0
CY2019 usnu Increase Decrease In Operating Lease Right Of Use Liability
IncreaseDecreaseInOperatingLeaseRightOfUseLiability
34000
CY2018 usnu Increase Decrease In Operating Lease Right Of Use Liability
IncreaseDecreaseInOperatingLeaseRightOfUseLiability
0
CY2018 usnu Accrued Distribution Equity Method Investment
AccruedDistributionEquityMethodInvestment
20000
CY2019 usnu Accrued Distribution Equity Method Investment
AccruedDistributionEquityMethodInvestment
20000
CY2018 usnu Capital Lease Obligations Increase
CapitalLeaseObligationsIncrease
833000
CY2019 usnu Capital Lease Obligations Increase
CapitalLeaseObligationsIncrease
0
CY2018 usnu Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
0
CY2019 usnu Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
33000
CY2019 usnu Operating Leases Deferred Rent Derecognition
OperatingLeasesDeferredRentDerecognition
15000
CY2018 usnu Operating Leases Deferred Rent Derecognition
OperatingLeasesDeferredRentDerecognition
0
CY2019 usnu Renovation Installation And Operation Agreement Period
RenovationInstallationAndOperationAgreementPeriod
P14Y
CY2019Q4 usnu Estimated Cost To Remove The Gamma Knife Agreement
EstimatedCostToRemoveTheGammaKnifeAgreement
620000
CY2018Q4 usnu Amount Of Guarantee Obligations Noncurrent
AmountOfGuaranteeObligationsNoncurrent
11000
CY2019Q4 usnu Amount Of Guarantee Obligations Noncurrent
AmountOfGuaranteeObligationsNoncurrent
11000
CY2018Q3 usnu Disposal Group Including Discontinued Operation Asset Retirement Obligations
DisposalGroupIncludingDiscontinuedOperationAssetRetirementObligations
537000
CY2019 usnu Maintenance Agreement
MaintenanceAgreement
P5Y
CY2019 usnu Warranty Term Of Maintenance Agreement
WarrantyTermOfMaintenanceAgreement
P1Y
CY2019Q4 usnu Basis Difference In Unconsolidated Entities Including Advances And Loans To Entities
BasisDifferenceInUnconsolidatedEntitiesIncludingAdvancesAndLoansToEntities
569000
CY2018Q4 usnu Basis Difference In Unconsolidated Entities Including Advances And Loans To Entities
BasisDifferenceInUnconsolidatedEntitiesIncludingAdvancesAndLoansToEntities
373000
CY2018Q4 usnu Deferred Tax Liabilities Excess Of Depreciation Over Book Depreciation
DeferredTaxLiabilitiesExcessOfDepreciationOverBookDepreciation
108000
CY2019Q4 usnu Deferred Tax Liabilities Excess Of Depreciation Over Book Depreciation
DeferredTaxLiabilitiesExcessOfDepreciationOverBookDepreciation
44000
CY2018Q4 usnu Deferred Tax Liability Net Effect Of Conversion From Accrual Basis Of Accounting To Cash Basis
DeferredTaxLiabilityNetEffectOfConversionFromAccrualBasisOfAccountingToCashBasis
2000
CY2019Q4 usnu Deferred Tax Liability Net Effect Of Conversion From Accrual Basis Of Accounting To Cash Basis
DeferredTaxLiabilityNetEffectOfConversionFromAccrualBasisOfAccountingToCashBasis
0
CY2019Q4 usnu Deferred Tax Assets Net Effect Of Conversion From Accrual Basis Of Accounting To Cash Basis
DeferredTaxAssetsNetEffectOfConversionFromAccrualBasisOfAccountingToCashBasis
18000
CY2018Q4 usnu Deferred Tax Assets Net Effect Of Conversion From Accrual Basis Of Accounting To Cash Basis
DeferredTaxAssetsNetEffectOfConversionFromAccrualBasisOfAccountingToCashBasis
0
CY2019Q4 usnu Total Lease Liabilities Operating And Finance
TotalLeaseLiabilitiesOperatingAndFinance
1132000
CY2019Q4 usnu Total Leased Assets Operating And Financing
TotalLeasedAssetsOperatingAndFinancing
1548000

Files In Submission

Name View Source Status
0001140361-20-008735-index-headers.html Edgar Link pending
0001140361-20-008735-index.html Edgar Link pending
0001140361-20-008735.txt Edgar Link pending
0001140361-20-008735-xbrl.zip Edgar Link pending
ex31_1.htm Edgar Link pending
ex32_1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
form10k.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
usnu-20191231.xml Edgar Link completed
usnu-20191231.xsd Edgar Link pending
usnu-20191231_cal.xml Edgar Link unprocessable
usnu-20191231_def.xml Edgar Link unprocessable
usnu-20191231_lab.xml Edgar Link unprocessable
usnu-20191231_pre.xml Edgar Link unprocessable